Global Market Study on Diabetic Nephropathy Asia to Witness Highest Growth by 2020
A latest market research report added to the repository of Market Research Reports Search Engine (MRRSE) states that the diabetic nephropathy market will report a moderate CAGR at 5.6% from 2014 through 2020.
The report, published by Persistence Market Research, is titled ‘Global Market
Study on Diabetic Nephropathy Market – Asia to Witness Highest Growth by 2020’.
The study says that the diabetic nephropathy market approximated US$2,262.2
million in 2014, and will be worth US$ 3,145.9 million by the end of 2020.
Diabetic nephropathy, a condition that increase the risk of
mortality in diabetes patients, is being widely reported across the world due
to the sheer increase in the number of obese people and diabetics. The disease
affects the kidneys, ultimately rendering them ineffective. This has
necessitated investments in formulating treatments for diabetic nephropathy,
leading to a teeming therapy pipeline in major markets of the world.
Browse Full Report
with TOC : http://www.mrrse.com/diabetic-nephropathy-market
The drugs, however, are faced with long approval times
(essentially because there are scores of regulatory hurdles) making it
difficult for pharma companies to bring novel products to the market in short
turnaround times. Moreover, there is a general lack of broader therapeutic
management for the disease. All of these factors will play a role in curtailing
the growth of the global diabetic nephropathy market.
The report notes that North America has the highest degree of
awareness about diabetic nephropathy. Government initiatives such as the
National Kidney Disease Education Program can be credited for this. The market
here continues to organically grow because of a parallel increase in the number
of people suffering from diabetes in America. Estimates from the SciELO Public
Health state that in 2000 about 35 million people in North America suffered from
diabetes mellitus; by 2025, this number will soar to 64 million in the region.
The
European diabetic nephropathy market is also on an upswing
because here too, diabetes is increasingly being reported. International
Diabetes Federation (IDF) says that the amount expended on diabetes treatment
in the European region was pegged at US$105.5 billion in 2010, and will hit
US$124.6 billion by 2030.
The highest potential for growth lies in the Asia Pacific
diabetic nephropathy market. The region is witnessing an escalation in the
incidence of diabetic nephropathy in Japan and other Southeast Asian nations.
Moving forward, companies in the diabetic nephropathy market
have a lucrative opportunity in developing combination therapies.
Send An Enquiry: http://www.mrrse.com/enquiry/119
Table of Content
Chapter 1 Preface
1.1 Report Description
1.2 Research Methodology
1.3 Assumptions
Chapter 2 Market
Synopsis
Chapter 3 Porter’s Five Forces Analysis
3.1 Bargaining Power of Suppliers
3.2 Bargaining Power of Buyers
3.3 Threat of New Entrants
3.4 Threat of Substitutes
3.5 Intensity of Rivalry
Chapter 4 Industry
Overview
4.1 Market Definition
4.2 Market Drivers
4.2.1 Increasing
prevalence of diabetes
4.2.2 Globally rising
obesity increasing the prevalence of diabetes
4.2.3 Increasing
R&D investments in drug discovery and development
4.2.4 Rising
awareness among people about diabetes and kidney-related disorders
4.3 Impact Analysis of Market Drivers
4.4 Market Restraints
4.4.1 Strict
regulatory requirements and long approval time for drugs
4.4.2 Lack of
comprehensive therapeutic management for diabetic nephropathy
4.5 Impact Analysis of Market Restraints
4.6 Market Trends
4.6.1 Increasing
usage of combination therapy is gaining popularity in diabetic nephropathy
market
Chapter 5 Global Market Size and Forecast
Chapter 6 Market Size and Forecast by Mode of
Treatment
6.1 Disease Modifying Therapies
6.1.1
Angiotensin-Converting Enzyme Inhibitors
6.1.2 Angiotensin
Receptor Blockers
6.1.3 Diuretics
6.1.4 Calcium Channel
Blockers
6.1.5 Renin
Inhibitors
6.1.6 Connective
Tissue Growth Factor Inhibitors
6.1.7 Antioxidant
Inflammation Modulator
6.1.8 Monocyte
Chemoattractant Proteins Inhibitor
6.1.9 Endothelin-A
Receptor Antagonist
6.1.10 G
Protein-Coupled Receptors
Chapter 7 Market Size and Forecast by
Geography
7.1 North America
7.1.1 Scenario in the
U.S.
7.1.2 Scenario in
Canada
7.2 Europe
7.2.1 Scenario in Germany
7.2.2 Scenario in
France
7.2.3 Scenario in the
U.K.
7.3 Asia
7.3.1 Scenario in
Japan
7.3.2 Scenario in
China
7.3.3 Scenario in
India
Chapter 8 Pipeline Drugs for Diabetic
Nephropathy
8.1 Drugs Under Development for Diabetic Nephropathy
Chapter 9 Competitive
Scenario
9.1 Competitive Benchmarking
Chapter 10 Company Profiles
10.1 Novartis AG
10.1.1 Company
overview
10.1.2 Products and
services
10.1.3 Financial
performance
10.1.4 Key developments
10.2 Merck & Co., Inc.
10.2.1 Company
overview
10.2.2 Products and
services
10.2.3 Financial
performance
10.2.4 Key
developments
10.3 Pfizer, Inc.
10.3.1 Company
overview
10.3.2 Products and
services
10.3.3 Financial
performance
10.3.4 Key
developments
10.4 Abbott Laboratories
10.4.1 Company
overview
10.4.2 Products and
services
10.4.3 Financial
performance
10.4.4 Key
developments
10.5 Sanofi
10.5.1 Company
overview
10.5.2 Products and
services
10.5.3 Financial
performance
10.5.4 Key
developments
10.6 Eli Lilly and Company
10.6.1 Company
overview
10.6.2 Products and
segments
10.6.3 Financial
performance
10.6.4 Key
developments
10.7 Reata Pharmaceuticals, Inc.
10.7.1 Company
overview
10.7.2 Products and
segments
10.7.3 Financial
performance
10.7.4 Key
developments
10.8 Bayer AG
10.8.1 Company
overview
10.8.2 Products and
segments
10.8.3 Financial
performance
10.8.4 Key
developments
10.9 AbbVie, Inc.
10.9.1 Company
overview
10.9.2 Products and
segments
10.9.3 Financial
performance
10.9.4 Key
developments
10.10 Mitsubishi Tanabe Pharma Corporation
10.10.1 Company
overview
10.10.2 Products and
segments
10.10.3 Financial
performance
10.10.4 Key
developments
About Us:
Market Research Reports Search Engine (MRRSE) is an
industry-leading database of market intelligence reports. Headquartered in New
York, U.S., MRRSE is driven by a stellar team of research experts and advisors
trained to offer objective advice. Our sophisticated search algorithm returns
results based on the report title, geographical region, publisher, or other
keywords.
MRRSE partners exclusively with leading global publishers to
provide clients single-point access to top-of-the-line market research. MRRSE’s
repository is updated every day to keep its clients ahead of the next new trend
in market research, be it competitive intelligence, product or service trends
or strategic consulting.
Contact
State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States
Telephone:
+1-518-618-1030
Email: sales@mrrse.com
Website: http://www.mrrse.com/
Comments
Post a Comment